IPO Timeline
Broker Results (T-2)
2021-07-14
Some brokers release in afternoon
Grey Market (T-1)
2021-07-15
Afternoon
HKEX Allotment (T-1)
2021-07-15
Evening
Registrar Allotment (T-1)
2021-07-15
Evening
Listing Day (T)
2021-07-16
First day of trading
Company Overview
| Stock Name | 康聖環球基因技術有限公司 |
|---|---|
| Stock Code | 09960 |
| Company Full Name | 康聖環球基因技術有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要在中國提供臨床檢測服務。 |
| Listing Date | 2021-07-16 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國湖北省武漢市東湖新技術開發區高新大道666號光谷生物城生物創新園D2-1 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.kindstar.com.cn |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 9.78 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 49.1% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 1,107,120,450 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 9.04 |
|---|---|
| First Day Open | HK$ 9.78 |
| First Day Change | -7.57% |
| First Day Volume | 97344700.0 |
| First Day Turnover | 905213000.0 |
Use of Proceeds
| Use of Proceeds | 1、約35%或718.8百萬港元將分配至銷售及營銷我們現有的特檢服務線以涵蓋更多醫院，尤其是三級醫院； 2、約20%或410.7百萬港元將分配至現有特檢服務線的研發，以采用創新檢測技術及持續擴大我們的檢測服務組合； 3、約15%或308.0百萬港元將分配至新特檢服務線的開發及商業化以進一步擴大我們的服務范圍； 4、約5%或102.7百萬港元將分配至撥資收購與我們的現有業務產生互補及協同效應的具吸引力的技術或檢測相關公司； 5、約10%或205.4百萬港元將分配至加強我們的檢測能力，包括擴充及升級我們的檢測設施、檢測設備及儀器以及招聘額外檢測及診斷技術人員； 6、約5%或102.7百萬港元將分配至向海外擴張至中國以外的市場，旨在滿足東南亞及中東發展中國家的未滿足醫療需求； 7、約10%或205.4百萬港元預期將用作營運資金及其他一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (3)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
Credit Suisse (Hong Kong) Limited CE AAO017
Overall Coordinators (3)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
Credit Suisse (Hong Kong) Limited CE AAO017
Joint Bookrunners (3)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
Credit Suisse (Hong Kong) Limited CE AAO017
Joint Lead Managers (6)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
Credit Suisse (Hong Kong) Limited CE AAO017
VMS Securities Limited CE AAC621
国泰君安证券（香港）有限公司 CE ABY236
富途证券国际（香港）有限公司 CE AZT137
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Athos Asia Event Driven Master Fund | 77,623,860 HKD | — | 3.51% | — | 6 months | 2022-01-16 |
| 2 | BlackRock Funds | 310,510,110 HKD | — | 14.02% | — | 6 months | 2022-01-16 |
| 3 | Carmignac Funds | 116,440,680 HKD | — | 5.26% | — | 6 months | 2022-01-16 |
| 4 | CPE Funds | 271,693,290 HKD | — | 12.27% | — | 6 months | 2022-01-16 |
| 5 | DNCA Finance | 116,440,680 HKD | — | 5.26% | — | 6 months | 2022-01-16 |
| 6 | Snow Lake China Master Fund, Ltd. | 155,252,610 HKD | — | 7.01% | — | 6 months | 2022-01-16 |
| 7 | 常春藤资产管理(香港)有限公司 | 38,811,930 HKD | — | 1.75% | — | 6 months | 2022-01-16 |
Directors & Management
| Chairman | 黃士昂 |
|---|---|
| Company Secretary | 柴海節 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 黃士昂及家族成員(14.73%);黃博(9.99%);HCA Health Investments Inc(9.16%);CK Lab Tech Investment Limited(8.08%);黃瑞瑨及關連人士(7.36%);涂贊兵(6.48%) |
|---|
IPO Timeline
